


This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended)

A compound of the formula I



wherein

R¹ is H, A or SO₂A,

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E is R²C=CR⁴ or R²R³C-CR⁴R⁵,

wherein

R², R³, R⁴ and R⁵ are each, independently of one another,

A, cycloalkyl having from 3 to 7 carbon atoms, Hal, ClI₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nN(R⁶)₂, (CH₂)_nN(R⁶)Ar, (CH₂)_nN(R⁶)Het, (CH₂)_nN(Ar)₂, (CH₂)_nN(Het)₂, (CH₂)_nCOOR⁶, (CH₂)_nCOOAr, (CH₂)_nCOOHet, (CH₂)_nCON(R⁶)₂, (CH₂)_nCON(R⁶)Ar, (CH₂)_nCON(R⁶)Het, (CH₂)_nCON(Ar)₂, (CH₂)_nCON(Het)₂, (CH₂)_nNR⁶COR⁶, (CH₂)_nNR⁶CON(R⁶)₂, (CH₂)_nNR⁶SO₂A, (CH₂)_nSO₂N(R⁶)₂, (CH₂)_nSO₂NR⁶(ClI₂)_mAr, (CH₂)_nSO₂NR⁶(CH₂)_mHet, (CH₂)_nS(O)_wR⁶, (CH₂)_nS(O)_wAr, (CH₂)_nS(O)_wHet, (CH₂)_nOOCR⁶, (CH₂)_nHet, (CH₂)_nAr, (CH₂)_nCOR⁶,

Serial No.: 10/511,155

-2-

MERCK-2932

$(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$, $(CH_2)_nCOO(CH_2)_mAr$,
 $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(Cl)_2Ar$,
 $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$, $(CH_2)_nS(CH_2)_mAr$,
 $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$,
 $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$,
 $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$,
 $(CH_2)_nCON(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)CO(CH_2)_mAr$,
 $(CH_2)_nCON(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $CH=N-OA$,
 $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^6$,
 $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$,
 $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$,
 $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$,
 $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$,
 $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$, $CH=CHCH_2NR^6Het$,
 $CH=CHCH_2N(R^6)_2$, $CH=CHCH_2OR^6$, $(CH_2)_nN(COOR^6)COOR^6$,
 $(CH_2)_nN(CONH_2)COOR^6$, $(CH_2)_nN(CONH_2)CONH_2$,
 $(CH_2)_nN(CH_2COOR^6)COOR^6$, $(CH_2)_nN(CH_2CONH_2)COOR^6$,
 $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^6COR^6$,
 $(CH_2)_nCHR^6COOR^6$, $(CH_2)_nCHR^6CH_2OR^6$, $(CH_2)_nOCN$ or
 $(CH_2)_nNCO$,

wherein

- R^6 is, independently, H, A or cycloalkyl having from 3 to 7 carbon atoms,
 Het is a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical which is unsubstituted or mono- or polysubstituted by A, Hal, NO_2 , CN, OR^6 , $N(R^6)_2$, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , $SO_2N(R^6)_2$, $S(O)_wA$ and/or $OOOR^6$,
 Ar is an aromatic hydrocarbon radical having from 6 to 14 carbon atoms

which is unsubstituted or mono- or polysubstituted by A, Hal, NO₂, CN, OR⁶, N(R⁶)₂, COOR⁶, CON(R⁶)₂, NR⁶COR⁶, NR⁶CON(R⁶)₂, NR⁶SO₂A, COR⁶, SO₂N(R⁶)₂, S(O)_wA and/or OOCR⁶,

w is 0, 1, 2 or 3, and

n and m, independently of one another, are 0, 1, 2, 3, 4 or 5;

X¹ is (CHR⁷)₃ or (CHR⁷)_n-Q-(CHR⁸)_k, wherein

Q is O, S, N-R⁶, (O-CHR⁷)₆, (CHR⁷-O)₈, CR⁹=CR¹⁰, (O-CHR⁷CHR¹⁰)₆, (CHR⁷CHR¹⁰-O)₈, C=O, C=S, C=NR⁶, CH(OR⁶), C(OR⁶)(OR⁶), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R⁶), N(R⁶)C(=O), C(=S)N(R⁶), N(R⁶)C(=S), OC(=O)N(R⁶), N(R⁶)C(=O)O, CH=N-O, CH=N-NR⁶, OC(O)NR⁶, NR⁶C(O)O, S=O, SO₂, SO₂NR⁶ or NR⁶SO₂,

g is 1, 2, 3, 4, 5 or 6,

~~h and k, independently of one another, are 0, 1, 2, 3, 4, 5 or 6,~~

and

R⁷, R⁸, R⁹, R¹⁰ and R¹², independently of one another, are as defined for R² to R⁵,

p is 0, 1, 2 or 3,

E is H, A, (CH₂)_nHet, (CH₂)_nAr or cycloalkyl having from 3 to 7 carbon atoms,

G is an optionally substituted alkylene radical having from 1 to 4 carbon atoms, where the substituents are selected from the meanings indicated for R⁴,

or

E and G, together with the N atom to which they are bonded, are an unsubstituted or substituted 5-, 6- or 7-membered, mono- or bicyclic heterocyclic radical, which may have 1, 2 or 3 further heteroatoms selected from N, O and S,

X^2 is a bond ~~or is selected, independently, from the meanings indicated for X^1 ,~~

Z is H or is a saturated, mono- or polyethylenically unsaturated or aromatic carbocyclic radical having from 5 to 10 carbon atoms or a saturated, mono- or polyethylenically unsaturated or aromatic heterocyclic radical having from 4 to 9 carbon atoms, where the carbocyclic or heterocyclic radical may be mono- or polysubstituted, where the substituents ~~are~~, independently of one another, comprise the meanings of R^2 to R^5 other than H, and wherein the heterocyclic radical contains from 1 to 4 heteroatoms which is, independently of one another, N, O or S,

and

Hal is F, Cl, Br or I,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 2. (Currently Amended)

The compound of the formula I according to

Claim 1, wherein

A is straight-chain alkyl having from 1 to 4 carbon atoms or branched alkyl having from 3 to 6 carbon atoms, and

D-E is $R^2C=CR^4$ or $R^2R^3C-CR^4R^5$,
in which R^2 , R^3 and R^5 are ~~selected~~, independently, from A or and cycloalkyl having from 3 to 7 carbon atoms,
and

R^4 is Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nCOOR^6$,

$(CH_2)_nCON(R^6)_2$, $(CH_2)_nNR^6COR^6$, $(CH_2)_nNR^6CON(R^6)_2$,
 $(CH_2)_nNR^6SO_2A$, $(CH_2)_nSO_2N(R^6)_2$, $(CH_2)_nS(O)_wA$, $(CH_2)_nOOCR^6$,
 $(CH_2)_nCOR^6$, $(CH_2)_nCO(CH_2)_mAr$, $(CH_2)_nCO(CH_2)_mHet$,
 $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$,
 $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nSR^6$,
 $(CH_2)_nS(CH_2)_mAr$, $(CH_2)_nS(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$,
 $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nCON(R^6)(CH_2)_mAr$,
 $(CH_2)_nN(R^6)CO(CH_2)_mAr$, $(CH_2)_nCON(R^6)(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CO(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nOCOR^6$,
 $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$,
 $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$,
 $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$,
 $(CH_2)_nN(R^6)CH_2CH_2OR^6$, $(CH_2)_nN(R^6)CH_2CH_2OCF_3$,
 $(CH_2)_nN(R^6)C(R^6)HCOOR^6$, $(CH_2)_nN(R^6)CH_2COHet$,
 $(CH_2)_nN(R^6)CH_2Het$, $(CH_2)_nN(R^6)CH_2CH_2N(R^6)CH_2COOR^6$,
 $(CH_2)_nN(R^6)CH_2CH_2N(R^6)_2$, $CH=CHCOOR^6$,
 $(CH_2)_nN(COOR^6)COOR^6$, $(CH_2)_nN(CONH_2)COOR^6$,
 $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^6)COOR^6$,
 $(CH_2)_nN(CH_2CONH_2)COOR^6$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^6COR^6$, $(CH_2)_nCHR^6COOR^6$ or $(CH_2)_nCHR^6CH_2OR^6$,

m is 0, 1, 2, 3, 4 or 5 and

n 0 or 1;

X¹ is $(CHR^7)_8$ wherein or $Q(CHR^8)_8$ in which

~~Q is selected from O, S, N-R⁶, (O-CHR⁷)₈, (CHR⁷-O)₈, CR⁶=CR¹⁰, (O-CHR⁶CHR¹⁰)₈, (CHR⁶CHR¹⁰-O)₈, C=O, C=S, C=NR⁶, C(OR⁶)(OR⁶), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R⁶), N(R⁶)C(=O),~~

$\text{OC}(=\text{O})\text{N}(\text{R}^6)$, $\text{N}(\text{R}^6)\text{C}(=\text{O})\text{O}$, $\text{CH}=\text{N}-\text{O}$, $\text{CH}=\text{N}-\text{NR}^6$, $\text{OC}(\text{O})\text{NR}^6$,
 $\text{NR}^6\text{C}(\text{O})\text{O}$, $\text{S}=\text{O}$, SO_2 , SO_2NR^6 and NR^6SO_2 ,

g is 2, 3 or 4,

k is 1, 2 or 3, and

R^7 , R^8 , R^9 and R^{10} are selected, independently, from comprises the meanings indicated for R^2 to R^5 ;

X^2 is a bond or independently is $(\text{CHR}^7)_g$ or $\text{Q}(\text{CHR}^8)_k$, in which


Q is selected from O , S , NR^6 , $(\text{O}-\text{CHR}^7)_g$, $(\text{CHR}^7-\text{O})_g$, $(\text{O}-\text{CHR}^8-\text{CHR}^{10})_g$, $(\text{CHR}^8-\text{CHR}^{10}-\text{O})_g$, $\text{C}=\text{O}$, $\text{CH}(\text{OR}^6)$, $\text{C}(=\text{O})\text{O}$, $\text{OC}(=\text{O})$, $\text{C}(=\text{O})\text{N}(\text{R}^6)$, $\text{N}(\text{R}^6)\text{C}(=\text{O})$, $\text{S}=\text{O}$, SO_2 , SO_2NR^6 and NR^6SO_2 , where
 g in X^2 is 1 or 2 and k in X^2 is 0 or 1, and

R^{12} is selected, independently, from comprises the meanings of R^4 other than H,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 3. (Currently Amended)

The compound according to Claim 1, of formula Ia,



wherein

R^1 , D-E and Z are as defined in claim 1 above, and wherein

X^1 is $(CHR^7)_g$ or $(CHR^7)_h-Q-(CHR^8)_k$, wherein

Q is $O, S, N-R^6, (O-CHR^7)_g, (CHR^7-O)_g, CR^9=CR^{10}, (O-CHR^9-CHR^{10})_g, (CHR^9-CHR^{10}-O)_g, C=O, C=S, C=NR^6, CH(OR^6), C(OR^6)(OR^6), C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^6), N(R^6)C(=O), OC(=O)N(R^6), N(R^6)C(=O)O, CH=N-O, CH=N-NR^6, OC(O)NR^6, NR^6C(O)O, S=O, SO_2, SO_2NR^6$ or NR^6SO_2 .

g is 1, 2, 3, 4, 5 or 6,

h and k , independently of one another, are 0, 1, 2, 3, 4, 5 or 6, and

R^6 is selected, independently, from H, A or cycloalkyl having from 3 to 7 carbon atoms,

R^7, R^8, R^9 and R^{10} are selected, independently, from comprises the meanings indicated for R^2 to R^5 ;

Y is CH, N, COR^{11} , CSR^{11} , an unsubstituted or substituted, spiro-linked carbocyclic radical having from 5 to 7 carbon atoms or an unsubstituted or substituted, spiro-linked, 5-, 6- or 7-membered heterocyclic radical having from 1 to 3 heteroatoms selected from which are N, S or O,

R^{11} is H, A, $(CH_2)_nHet$, $(CH_2)_nAr$ or cycloalkyl having from 3 to 7 carbon atoms,

X^2 is a bond or $O, S, N-R^7, CH_2$ or CH_2CH_2 .

p, q and r , independently of one another, are 0, 1, 2 or 3 and

Hal is F, Cl, Br or I, and

R^{12} and R^{13} , are each, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$,

NO₂, CN, COOR^o, CON(R^o)₂, NR^oCOR^o, NR^oCON(R^o)₂, NR^oSO₂A,
COR^o, SO₂NR^o, S(O)_wA, OOCR^o ~~and/or~~ or C(NH)NOH,

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 4. (Previously Presented)

A compound which is

- a) 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- b) 6-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- c) 6-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- d) 4-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- e) 4-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- f) 4-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- g) 5-{3-[4-(4-fluorophenoxy)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- h) 5-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- i) 5-{3-[4-(2,4-difluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile;
- j) 5-{3-[4-(4-cyanophenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- k) 5-{4-[3-(3-cyano-1H-indol-6-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;
- l) 5-{3-[4-(2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- m) 5-{4-[3-(3-cyano-1H-indol-4-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;
- n) 5-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}benzofuran-2-carboxamide;
- o) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1-methanesulfonyl-1H-indole-3-carbonitrile;
- p) 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;
- q) 5-[3-(4-benzo[1,2,5]thiadiazol-4-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;


- r) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carboxamide;
- s) 5-[3-(4-quinolin-8-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;
- t) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- u) 1-methanesulfonyl-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1H-indole-3-carbonitrile;
- v) 5-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- w) 5-{3-[4-(1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- x) 5-{3-[4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- y) 3-{1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-yl}-1H-indole-5-carbonitrile;
- z) 5-{3-[4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- aa) 5-{3-[4-(4-fluoro-1H-indol-3-yl)piperidin-1-yl]propyl}-1H-indole-3-carbonitrile;
- bb) 5-[3-(4-benzo[d]isothiazol-3-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- cc) 4-{1-[3-(3-cyano-1H-indol-6-yl)propyl]piperidin-4-yloxy}benzamide;
- dd) 6-{3-[4-(2-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- ee) 6-{3-[4-(4-cyano-3-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- ff) 6-{3-[4-(4-cyano-2-methoxyphenyl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;
- gg) 4-[3-(4-pyrazol-1-ylmethyl-1-piperidyl)propyl]-1H-indole-3-carbonitrile;
- hh) N-(6-{4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)acetamide;
- ii) 5-{3-[(pyridin-3-ylmethyl)amino]propyl}-1H-indole-3-carbonitrile;
- jj) 5-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl]propyl}-1H-indole-3-carbonitrile;

- kk) 5-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1H-indole-3-carbonitrile;
- ll) 5-[3-[(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amino]propyl]-1H-indole-3-carbonitrile;
- mm) 5-[3-[4-(3-methoxyphenyl)-3-methylpiperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- nn) 5-[3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- oo) N-(4-[1-[3-(3-cyano-1H-indol-5-yl)propyl]piperidin-4-ylmethyl]-phenyl)acetamide;
- pp) 5-[3-[4-(4-pyridin-3-ylthiazol-2-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- qq) ethyl 2-[4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl]-thiazole-4-carboxylate;
- rr) 5-[3-[3-(2-oxopyrrolidin-1-yl)propylamino]propyl]-1H-indole-3-carbonitrile;
- ss) ethyl (6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl]-2-oxo-2H-chromen-3-yl)carbamate;
- tt) 5-[3-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]propyl]-1H-indole-3-carbonitrile;
- uu) methyl (6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazin-1-yl]-2-oxo-2H-chromen-3-yl)carbamate;
- vv) 2-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-piperazin-1-yl]thiazole-4-carboxamide; or
- ww) 4-[3-(3-cyano-1H-indol-5-yl)propyl]piperazine-1-thiocarboxamide;
- or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture thereof.

Claim 5. (Currently Amended)

A process for the preparation of a compound of formula I according to Claim 1 or a salt thereof comprising reacting


- a) a compound of the formula II



wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group, and R^1 , D, E, R^{12} , p and X^1 are as defined in Claim 1,

b) with a compound of the formula III



wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1,

and optionally

c) converting the resultant compound of the formula I into a salt by treatment with an acid.

Claim 6. (Previously Presented) A process for the preparation of a pharmaceutical composition, comprising converting a compound of Claim 1 into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

Claim 7. (Previously Presented) A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 8. (Cancelled)

Claim 9. (Previously Presented) A method for inhibiting the activity of an excitatory amino acid in a cell, comprising contacting said cell with a compound of claim 1.

Claim 10. (Previously Presented) A method for inhibiting the activity of a glycine transporter comprising contacting said transporter with a compound of claim 1.

Claim 11. (Cancelled)

Claim 12. (Previously Presented) A method for treating a 5HT-mediated disease comprising administering to a host in need thereof a compound of claim 1.

Claim 13. (Currently Amended) ~~A~~ The method according to Claim 12, wherein said disease is depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain and spinal cord trauma, obsessive-compulsive disorder, sleeping disorder disorders, tardive dyskinesia, learning disorder disorders, age-related memory disorder disorders, eating disorder disorders, and/or or sexual dysfunction dysfunctions.

Claim 14. (Previously Presented) A method for treating schizophrenia, depression, dementia, Parkinson's disease, Alzheimer's disease, Lewy bodies dementia, Huntington's disease, Tourette's syndrome, anxiety, learning and memory impairments, neurodegenerative diseases, cognitive impairments, nicotine dependence or pain comprising administering to a host in need thereof a compound of claim 1.


Claim 15. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a host in need thereof a compound of claim 1.

Claim 16. (Previously Presented) A method for combating neurodegenerative diseases, cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction or psychoses comprising administering to a

host in need thereof a pharmaceutical composition of claim 7.

Claim 17. (Cancelled)


Claim 18. (Withdrawn, Currently Amended) A compound of the formula II



wherein

L^1 is Cl, Br, I, OH, a reactively esterified OH group or a diazonium group,
and R^1 , D, E, R^{12} , p and X^1 are as defined in Claim 1.


Claim 19. (Withdrawn, Currently Amended) A compound of the formula III



wherein

L^2 is H or a metal ion, and E, G, X^2 and Z are as defined in Claim 1.

Claim 20. (Currently Amended) A compound of the formula Ia



wherein

R^1 is H, A or SO_2A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^4$, wherein R^2 is H or methyl and R^4 is CN

X^1 is $(CHR^7)_g$

g is 1, 2, 3, 4, 5 or 6,

R^7 is ~~selected~~, independently, ~~from~~ has the meanings indicated for R^2 to R^5 ;


Y is CH or N,


q is 0,

p and r are each, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,
 R^{12} and R^{13} , are each, independently of one another, ~~are selected from the meanings of R^4 other than H and~~ or are, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOOR^6$ ~~and/or~~ or $C(NH)NOH$, and

X^2-Z is at least one of ~~selected from the group consisting of~~





wherein

X^2 is a bond,

R^{14} is selected, independently, from Hal, A, $(CH_2)_nHet$, $(CH_2)_nAr$, $(CH_2)_nCOO(CH_2)_mAr$, $(CH_2)_nCOO(CH_2)_mHet$, $(CH_2)_nOR^6$, $(CH_2)_nO(CH_2)_mAr$, $(CH_2)_nO(CH_2)_mHet$, $(CH_2)_nN(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)(CH_2)_mHet$, $(CH_2)_nSO_2N(R^6)(CH_2)_mAr$, $(CH_2)_nN(R^6)SO_2(CH_2)_mAr$, $(CH_2)_nSO_2N(R^6)(CH_2)_mHet$, $(CH_2)_nN(R^6)SO_2(CH_2)_mHet$, $(CH_2)_nN(R^6)_2$, $(CH_2)_nNHOA$, $(CH_2)_n(R^6)Het$, $(CH_2)_nOCOR^6$, $(CH_2)_nOC(O)N(R^6)_2$, $(CH_2)_nOC(O)NR^6(CH_2)_mAr$, $(CH_2)_nOC(O)NR^6(CH_2)_mHet$, $(CH_2)_nNR^6COOR^6$, $(CH_2)_nNR^6COO(CH_2)_mAr$, $(CH_2)_nNR^6COO(CH_2)_mHet$, or CN

w is 0, 1, 2 or 3,

t is 0, 1, 2, 3, 4 or 5, and

m is 0, 1, 2, 3, 4, or 5


n is 0, 1, 2, or 3

R' is H, A, (CH₂)_mHet, (CH₂)_nAr, cycloalkyl having from 3 to 7 carbon atoms or SO₂A;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof


Claim 21. (Currently Amended)

A compound of the formula IIa




wherein R¹ and R² are as defined in claim 20; and

Y-Z is a radical which comprises at least one of the formulae




or a radical which comprises at least one of the formulae



or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.

Claim 22. (Currently Amended)
claim 20

A compound of the formula Ia according to



wherein

Serial No.: 10/511,155

-19-

MERCK-2932

R^1 is H or A

A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, and

D-E $R^2C=CR^3$, wherein R^2 is H or methyl and R^3 is CN

X^1 is $(CHR^7)_g$

g is 3,

R^7 is selected, independently, from has the meanings indicated for R^2 to R^5 ;

Y is CH or N,


q is 0,


p and r are, independently of one another, 0, 1, 2 or 3

Hal is F, Cl, Br or I,

R^{12} and R^{13} , are, independently of one another, Hal, CN, NO_2 , OR^6 , $N(R^6)_2$, NO_2 , CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOOR^6$ and/or $OR^6C(NH)NOH$, and

X^2-Z is at least one of selected from the group consisting of





wherein

X^2 is a bond,

R^{14} is selected, independently, from Hal, NO_2 , OR^6 , $N(R^6)_2$, CN, $COOR^6$, $CON(R^6)_2$, NR^6COR^6 , $NR^6CON(R^6)_2$, NR^6SO_2A , COR^6 , SO_2NR^6 , $S(O)_wA$, $OOOR^6$ and/or $C(NH)NOH$,

w is 0, 1, 2 or 3,

t is 1, 2, 3, and

R' is H, A, $(CH_2)_nHcr$, $(CH_2)_nAr$, cycloalkyl having from 3 to 7 carbon atoms or SO_2A ;

or a pharmaceutically salt, solvate, stereoisomer, or mixture thereof.